SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives which addresses the significant unmet therapeutic needs. It is currently developing a lead product candidate, SCY-078, a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Durham, NC.
